Udo Oppermann

Professor Udo Oppermann serves as Professor of Molecular Biology and Director of Laboratory Sciences at the Institute of Musculoskeletal Sciences, Botnar Research Centre, University of Oxford. He is also Deputy Director of the Oxford Centre of Translational Myeloma Research and a fellow at St Catherine's College.

His educational background includes a Diploma in Human Biology (1990) and PhD in Pharmacology and Toxicology (1994), both earned with distinctions from Philipps University Marburg. Prior academic appointments include Associate Professor at Karolinska Institutet (until 2004) and sabbatical work at Yale University.

Research focuses on epigenetic mechanisms in disease through drug and target discovery using systems biology and single-cell approaches. Key disease targets include metabolic disorders, inflammatory conditions, and malignant diseases—particularly multiple myeloma and secondary bone cancers. His group pioneers chemical biology applications in primary tumor microenvironments.

Current funding sources include Cancer Research UK, Innovate UK, EPSRC, Royal Society-Newton Fund, Bristol Myers Squibb, Bayer Healthcare, GlaxoSmithKline, Blood Cancer UK, and Leducq Foundation.

Notable research trends show increasing emphasis on epigenetic regulation in immune cells (2020-2024), single-cell technologies for myeloma (2022-2024), and translational applications of chromatin modifiers (2016-2019). Recent work integrates metabolomics with epigenetic mechanisms in gynecological and hematological disorders.

He supervises doctoral research including Singh K.'s 2024 thesis on sonodynamic therapy mechanisms. Leadership roles encompass directing Oxford's Molecular Laboratory Sciences division and co-leading translational myeloma research initiatives.